SUSTAIN 6 Trial In this trial, new or worsening nephropathy, defined as persistent macroalbuminuria, persistent doubling of the serum creatinine, or a creatinine clearance 339 mg/mmol), a sustained decline in eGFR of 30% or more from baseline, or chronic renal replacement therapy (322)
Compared with placebo, weight loss achieved with all doses of cagrilintide was statistically significant, estimated difference range was 3.0 Percentage to 7.8 Percentage (P less than 0.001) [9]
Because of this and other challenges, employers arent seeing a significant return on their investment or improvements in their employees health. Part of the reason for this low adherence may be attributed to the fact that it can take several months for individuals to work up to the full, effective dose and that some may experience uncomfortable side effects, such as nausea, diarrhea, constipation, vomiting and other gastrointestinal issues contributing to the 10% increase in ER visits that were seen among members after starting a GLP-1
A.BeardwellC